N/A N=94 Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Manufacturing Technology
Visual Acuity
Primary: Overall Comfort Score — 56.52; 55.72 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Catheter System Feasibility Clinical Trial
Renal Insufficiency, Chronic
Primary: Number of Participants With Sufficient Patency for Clinical Access — 20 Participants
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Phase 2 N=32 Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
Parkinson's Disease
Primary: Number of Participants With Treatment Emergent Adverse Events — 5; 5; 3; 4 Participants
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
Phase 2 N=34 Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
Celiac Disease
Primary: Change From Baseline in Interferon-Gamma Spot Forming Units (IFN-gamma SFUs) in a Gliadin-specific Enzyme-linked Immunospot (ELISpot) at Day 20 — 3.08; 1.98; 2.01; 17.57…
Phase 1 N=30 Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
Bioequivalence
Primary: AUC0-tlast of Favipiravir — 9641.989; 9907.170 ng*hr/mL — p=0.0000
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=116 Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents
Allergic Contact Dermatitis
Primary: Number of Participants With Negative, Positive, Irritant or Doubtful Reaction Scores — 49; 3; 0; 1 Participants
Phase 2 N=57 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Solid Tumours
Primary: Percentage of Participants Achieving Objective Response Rate (ORR) in Subjects' With Tumors of Primary Interest (RMS, NRSTS or Ewing Sarcoma/pPNET) — 8.3; 0.0; 0.0…
Phase 2 N=308 Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Stage III Oropharyngeal Squamous Cell Carcinoma · Stage IVA Oropharyngeal Squamous Cell Carcinoma · Stage IVB Oropharyngeal Squamous Cell Carcinoma
Primary: Percentage of Participants Alive Without Progression at Two Years (Progression-free Survival) — 90.5; 87.6 percentage of participants — p=0.04
Phase 2 N=53 A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Testosterone Levels — 1.02; 1.05 ng/dL — p=0.4879
Phase 2 N=81 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
N/A N=22 End-of-Life Care for African Americans
Colonic Neoplasms · Breast Neoplasms · Lung Neoplasms
Primary: Intent to Discuss Advance Directives (Based on the Transtheoretical Stages of Change Model) — 0; 1; 1; 3 Participants
Phase 4 N=64 Use of On-Q Pump for Pain Post C-Section
Pain
Primary: Change in Pain Scores During Cough From Baseline — 4; 1; 20.5; 10 score on a scale